EGFR and non-small cell lung carcinoma: Later, the third generation of EGFRi (Figure 1) selective to EGFRL858R/T790M was developed (e.g., osimertinib) and seemed to help as an alternative against NSCLC patients resistant to the first generation EGFR‐inhibitor [26, 27, 28].